[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |
Advanced search

United States Relapsed Acute Myeloid Leukemia Drug Market Report 2018

February 2018 | 109 pages | ID: U1C68624E56EN
QYResearch

US$ 3,800.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
In this report, the United States Relapsed Acute Myeloid Leukemia Drug market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025.

Geographically, this report splits the United States market into seven regions:
  • The West
  • Southwest
  • The Middle Atlantic
  • New England
  • The South
  • The Midwest
  • with sales (volume), revenue (value), market share and growth rate of Relapsed Acute Myeloid Leukemia Drug in these regions, from 2013 to 2025 (forecast).
United States Relapsed Acute Myeloid Leukemia Drug market competition by top manufacturers/players, with Relapsed Acute Myeloid Leukemia Drug sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
  • 4SC AG
  • AbbVie Inc.
  • Actinium Pharmaceuticals, Inc.
  • Agios Pharmaceuticals, Inc.
  • Amgen Inc.
  • Arog Pharmaceuticals, Inc.
  • Array BioPharma Inc.
  • Astellas Pharma Inc.
  • Astex Pharmaceuticals, Inc.
  • AstraZeneca Plc
  • AVEO Pharmaceuticals, Inc.
  • BioLineRx, Ltd.
  • Boehringer Ingelheim GmbH
  • Boston Biomedical, Inc.
  • Bristol-Myers Squibb Company
  • Calithera Biosciences, Inc.
  • Celgene Corporation
  • Cornerstone Pharmaceuticals, Inc.
  • CTI BioPharma Corp.
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
  • aNK Program
  • AT-9283
  • BI-836858
  • binimetinib
  • BL-8040
  • Others
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
  • Clinic
  • Hospital
  • Others
If you have any special requirements, please let us know and we will offer you the report as you want.
United States Relapsed Acute Myeloid Leukemia Drug Market Report 2018

1 RELAPSED ACUTE MYELOID LEUKEMIA DRUG OVERVIEW

1.1 Product Overview and Scope of Relapsed Acute Myeloid Leukemia Drug
1.2 Classification of Relapsed Acute Myeloid Leukemia Drug by Product Category
  1.2.1 United States Relapsed Acute Myeloid Leukemia Drug Market Size (Sales Volume) Comparison by Type (2013-2025)
  1.2.2 United States Relapsed Acute Myeloid Leukemia Drug Market Size (Sales Volume) Market Share by Type (Product Category) in 2017
  1.2.3 aNK Program
  1.2.4 AT-9283
  1.2.5 BI-836858
  1.2.6 binimetinib
  1.2.7 BL-8040
  1.2.8 Others
1.3 United States Relapsed Acute Myeloid Leukemia Drug Market by Application/End Users
  1.3.1 United States Relapsed Acute Myeloid Leukemia Drug Market Size (Consumption) and Market Share Comparison by Application (2013-2025)
  1.3.2 Clinic
  1.3.3 Hospital
  1.3.4 Others
1.4 United States Relapsed Acute Myeloid Leukemia Drug Market by Region
  1.4.1 United States Relapsed Acute Myeloid Leukemia Drug Market Size (Value) Comparison by Region (2013-2025)
  1.4.2 The West Relapsed Acute Myeloid Leukemia Drug Status and Prospect (2013-2025)
  1.4.3 Southwest Relapsed Acute Myeloid Leukemia Drug Status and Prospect (2013-2025)
  1.4.4 The Middle Atlantic Relapsed Acute Myeloid Leukemia Drug Status and Prospect (2013-2025)
  1.4.5 New England Relapsed Acute Myeloid Leukemia Drug Status and Prospect (2013-2025)
  1.4.6 The South Relapsed Acute Myeloid Leukemia Drug Status and Prospect (2013-2025)
  1.4.7 The Midwest Relapsed Acute Myeloid Leukemia Drug Status and Prospect (2013-2025)
1.5 United States Market Size (Value and Volume) of Relapsed Acute Myeloid Leukemia Drug (2013-2025)
  1.5.1 United States Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2013-2025)
  1.5.2 United States Relapsed Acute Myeloid Leukemia Drug Revenue and Growth Rate (2013-2025)

2 UNITED STATES RELAPSED ACUTE MYELOID LEUKEMIA DRUG MARKET COMPETITION BY PLAYERS/SUPPLIERS

2.1 United States Relapsed Acute Myeloid Leukemia Drug Sales and Market Share of Key Players/Suppliers (2013-2018)
2.2 United States Relapsed Acute Myeloid Leukemia Drug Revenue and Share by Players/Suppliers (2013-2018)
2.3 United States Relapsed Acute Myeloid Leukemia Drug Average Price by Players/Suppliers (2013-2018)
2.4 United States Relapsed Acute Myeloid Leukemia Drug Market Competitive Situation and Trends
  2.4.1 United States Relapsed Acute Myeloid Leukemia Drug Market Concentration Rate
  2.4.2 United States Relapsed Acute Myeloid Leukemia Drug Market Share of Top 3 and Top 5 Players/Suppliers
  2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Relapsed Acute Myeloid Leukemia Drug Manufacturing Base Distribution, Sales Area, Product Type

3 UNITED STATES RELAPSED ACUTE MYELOID LEUKEMIA DRUG SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2013-2018)

3.1 United States Relapsed Acute Myeloid Leukemia Drug Sales and Market Share by Region (2013-2018)
3.2 United States Relapsed Acute Myeloid Leukemia Drug Revenue and Market Share by Region (2013-2018)
3.3 United States Relapsed Acute Myeloid Leukemia Drug Price by Region (2013-2018)

4 UNITED STATES RELAPSED ACUTE MYELOID LEUKEMIA DRUG SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2013-2018)

4.1 United States Relapsed Acute Myeloid Leukemia Drug Sales and Market Share by Type (Product Category) (2013-2018)
4.2 United States Relapsed Acute Myeloid Leukemia Drug Revenue and Market Share by Type (2013-2018)
4.3 United States Relapsed Acute Myeloid Leukemia Drug Price by Type (2013-2018)
4.4 United States Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate by Type (2013-2018)

5 UNITED STATES RELAPSED ACUTE MYELOID LEUKEMIA DRUG SALES (VOLUME) BY APPLICATION (2013-2018)

5.1 United States Relapsed Acute Myeloid Leukemia Drug Sales and Market Share by Application (2013-2018)
5.2 United States Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate by Application (2013-2018)
5.3 Market Drivers and Opportunities

6 UNITED STATES RELAPSED ACUTE MYELOID LEUKEMIA DRUG PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 4SC AG
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Relapsed Acute Myeloid Leukemia Drug Product Category, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 4SC AG Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.1.4 Main Business/Business Overview
6.2 AbbVie Inc.
  6.2.2 Relapsed Acute Myeloid Leukemia Drug Product Category, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.2.4 Main Business/Business Overview
6.3 Actinium Pharmaceuticals, Inc.
  6.3.2 Relapsed Acute Myeloid Leukemia Drug Product Category, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.3.4 Main Business/Business Overview
6.4 Agios Pharmaceuticals, Inc.
  6.4.2 Relapsed Acute Myeloid Leukemia Drug Product Category, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.4.4 Main Business/Business Overview
6.5 Amgen Inc.
  6.5.2 Relapsed Acute Myeloid Leukemia Drug Product Category, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.5.4 Main Business/Business Overview
6.6 Arog Pharmaceuticals, Inc.
  6.6.2 Relapsed Acute Myeloid Leukemia Drug Product Category, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.6.4 Main Business/Business Overview
6.7 Array BioPharma Inc.
  6.7.2 Relapsed Acute Myeloid Leukemia Drug Product Category, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.7.4 Main Business/Business Overview
6.8 Astellas Pharma Inc.
  6.8.2 Relapsed Acute Myeloid Leukemia Drug Product Category, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.8.4 Main Business/Business Overview
6.9 Astex Pharmaceuticals, Inc.
  6.9.2 Relapsed Acute Myeloid Leukemia Drug Product Category, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.9.4 Main Business/Business Overview
6.10 AstraZeneca Plc
  6.10.2 Relapsed Acute Myeloid Leukemia Drug Product Category, Application and Specification
    6.10.2.1 Product A
    6.10.2.2 Product B
  6.10.3 AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.10.4 Main Business/Business Overview
6.11 AVEO Pharmaceuticals, Inc.
6.12 BioLineRx, Ltd.
6.13 Boehringer Ingelheim GmbH
6.14 Boston Biomedical, Inc.
6.15 Bristol-Myers Squibb Company
6.16 Calithera Biosciences, Inc.
6.17 Celgene Corporation
6.18 Cornerstone Pharmaceuticals, Inc.
6.19 CTI BioPharma Corp.

7 RELAPSED ACUTE MYELOID LEUKEMIA DRUG MANUFACTURING COST ANALYSIS

7.1 Relapsed Acute Myeloid Leukemia Drug Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Relapsed Acute Myeloid Leukemia Drug

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Relapsed Acute Myeloid Leukemia Drug Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Relapsed Acute Myeloid Leukemia Drug Major Manufacturers in 2017
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 UNITED STATES RELAPSED ACUTE MYELOID LEUKEMIA DRUG MARKET SIZE (VALUE AND VOLUME) FORECAST (2018-2025)

11.1 United States Relapsed Acute Myeloid Leukemia Drug Sales Volume, Revenue Forecast (2018-2025)
11.2 United States Relapsed Acute Myeloid Leukemia Drug Sales Volume Forecast by Type (2018-2025)
11.3 United States Relapsed Acute Myeloid Leukemia Drug Sales Volume Forecast by Application (2018-2025)
11.4 United States Relapsed Acute Myeloid Leukemia Drug Sales Volume Forecast by Region (2018-2025)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer

The report requires updating with new data and is sent in 2-3 business days after order is placed.
LIST OF TABLES AND FIGURES

Figure Product Picture of Relapsed Acute Myeloid Leukemia Drug
Figure United States Relapsed Acute Myeloid Leukemia Drug Market Size (K Pcs) by Type (2013-2025)
Figure United States Relapsed Acute Myeloid Leukemia Drug Sales Volume Market Share by Type (Product Category) in 2017
Figure aNK Program Product Picture
Figure AT-9283 Product Picture
Figure BI-836858 Product Picture
Figure binimetinib Product Picture
Figure BL-8040 Product Picture
Figure Others Product Picture
Figure United States Relapsed Acute Myeloid Leukemia Drug Market Size (K Pcs) by Application (2013-2025)
Figure United States Sales Market Share of Relapsed Acute Myeloid Leukemia Drug by Application in 2017
Figure Clinic Examples
Table Key Downstream Customer in Clinic
Figure Hospital Examples
Table Key Downstream Customer in Hospital
Figure Others Examples
Table Key Downstream Customer in Others
Figure United States Relapsed Acute Myeloid Leukemia Drug Market Size (Million USD) by Region (2013-2025)
Figure The West Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure Southwest Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure The Middle Atlantic Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure New England Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure The South of US Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure The Midwest Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure United States Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) and Growth Rate (2013-2025)
Figure United States Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure United States Relapsed Acute Myeloid Leukemia Drug Market Major Players Product Sales Volume (K Pcs) (2013-2018)
Table United States Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) of Key Players/Suppliers (2013-2018)
Table United States Relapsed Acute Myeloid Leukemia Drug Sales Share by Players/Suppliers (2013-2018)
Figure 2017 United States Relapsed Acute Myeloid Leukemia Drug Sales Share by Players/Suppliers
Figure 2017 United States Relapsed Acute Myeloid Leukemia Drug Sales Share by Players/Suppliers
Figure United States Relapsed Acute Myeloid Leukemia Drug Market Major Players Product Revenue (Million USD) (2013-2018)
Table United States Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) by Players/Suppliers (2013-2018)
Table United States Relapsed Acute Myeloid Leukemia Drug Revenue Share by Players/Suppliers (2013-2018)
Figure 2017 United States Relapsed Acute Myeloid Leukemia Drug Revenue Share by Players/Suppliers
Figure 2017 United States Relapsed Acute Myeloid Leukemia Drug Revenue Share by Players/Suppliers
Table United States Market Relapsed Acute Myeloid Leukemia Drug Average Price (USD/Pcs) of Key Players/Suppliers (2013-2018)
Figure United States Market Relapsed Acute Myeloid Leukemia Drug Average Price (USD/Pcs) of Key Players/Suppliers in 2017
Figure United States Relapsed Acute Myeloid Leukemia Drug Market Share of Top 3 Players/Suppliers
Figure United States Relapsed Acute Myeloid Leukemia Drug Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Relapsed Acute Myeloid Leukemia Drug Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Relapsed Acute Myeloid Leukemia Drug Product Category
Table United States Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) by Region (2013-2018)
Table United States Relapsed Acute Myeloid Leukemia Drug Sales Share by Region (2013-2018)
Figure United States Relapsed Acute Myeloid Leukemia Drug Sales Share by Region (2013-2018)
Figure United States Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Region in 2017
Table United States Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Market Share by Region (2013-2018)
Table United States Relapsed Acute Myeloid Leukemia Drug Revenue Share by Region (2013-2018)
Figure United States Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Region (2013-2018)
Figure United States Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Region in 2017
Table United States Relapsed Acute Myeloid Leukemia Drug Price (USD/Pcs) by Region (2013-2018)
Table United States Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) by Type (2013-2018)
Table United States Relapsed Acute Myeloid Leukemia Drug Sales Share by Type (2013-2018)
Figure United States Relapsed Acute Myeloid Leukemia Drug Sales Share by Type (2013-2018)
Figure United States Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Type in 2017
Table United States Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Market Share by Type (2013-2018)
Table United States Relapsed Acute Myeloid Leukemia Drug Revenue Share by Type (2013-2018)
Figure Revenue Market Share of Relapsed Acute Myeloid Leukemia Drug by Type (2013-2018)
Figure Revenue Market Share of Relapsed Acute Myeloid Leukemia Drug by Type in 2017
Table United States Relapsed Acute Myeloid Leukemia Drug Price (USD/Pcs) by Types (2013-2018)
Figure United States Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate by Type (2013-2018)
Table United States Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) by Application (2013-2018)
Table United States Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application (2013-2018)
Figure United States Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application (2013-2018)
Figure United States Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application in 2017
Table United States Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate by Application (2013-2018)
Figure United States Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate by Application (2013-2018)
Table 4SC AG Basic Information List
Table 4SC AG Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure 4SC AG Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate (2013-2018)
Figure 4SC AG Relapsed Acute Myeloid Leukemia Drug Sales Market Share in United States (2013-2018)
Figure 4SC AG Relapsed Acute Myeloid Leukemia Drug Revenue Market Share in United States (2013-2018)
Table AbbVie Inc. Basic Information List
Table AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate (2013-2018)
Figure AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Sales Market Share in United States (2013-2018)
Figure AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Revenue Market Share in United States (2013-2018)
Table Actinium Pharmaceuticals, Inc. Basic Information List
Table Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate (2013-2018)
Figure Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales Market Share in United States (2013-2018)
Figure Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Revenue Market Share in United States (2013-2018)
Table Agios Pharmaceuticals, Inc. Basic Information List
Table Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate (2013-2018)
Figure Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales Market Share in United States (2013-2018)
Figure Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Revenue Market Share in United States (2013-2018)
Table Amgen Inc. Basic Information List
Table Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate (2013-2018)
Figure Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Sales Market Share in United States (2013-2018)
Figure Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Revenue Market Share in United States (2013-2018)
Table Arog Pharmaceuticals, Inc. Basic Information List
Table Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate (2013-2018)
Figure Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales Market Share in United States (2013-2018)
Figure Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Revenue Market Share in United States (2013-2018)
Table Array BioPharma Inc. Basic Information List
Table Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate (2013-2018)
Figure Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales Market Share in United States (2013-2018)
Figure Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Revenue Market Share in United States (2013-2018)
Table Astellas Pharma Inc. Basic Information List
Table Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate (2013-2018)
Figure Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales Market Share in United States (2013-2018)
Figure Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Revenue Market Share in United States (2013-2018)
Table Astex Pharmaceuticals, Inc. Basic Information List
Table Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate (2013-2018)
Figure Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales Market Share in United States (2013-2018)
Figure Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Revenue Market Share in United States (2013-2018)
Table AstraZeneca Plc Basic Information List
Table AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate (2013-2018)
Figure AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Sales Market Share in United States (2013-2018)
Figure AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Revenue Market Share in United States (2013-2018)
Table AVEO Pharmaceuticals, Inc. Basic Information List
Table BioLineRx, Ltd. Basic Information List
Table Boehringer Ingelheim GmbH Basic Information List
Table Boston Biomedical, Inc. Basic Information List
Table Bristol-Myers Squibb Company Basic Information List
Table Calithera Biosciences, Inc. Basic Information List
Table Celgene Corporation Basic Information List
Table Cornerstone Pharmaceuticals, Inc. Basic Information List
Table CTI BioPharma Corp. Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Relapsed Acute Myeloid Leukemia Drug
Figure Manufacturing Process Analysis of Relapsed Acute Myeloid Leukemia Drug
Figure Relapsed Acute Myeloid Leukemia Drug Industrial Chain Analysis
Table Raw Materials Sources of Relapsed Acute Myeloid Leukemia Drug Major Players/Suppliers in 2017
Table Major Buyers of Relapsed Acute Myeloid Leukemia Drug
Table Distributors/Traders List
Figure United States Relapsed Acute Myeloid Leukemia Drug Sales Volume (K Pcs) and Growth Rate Forecast (2018-2025)
Figure United States Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate Forecast (2018-2025)
Figure United States Relapsed Acute Myeloid Leukemia Drug Price (USD/Pcs) Trend Forecast (2018-2025)
Table United States Relapsed Acute Myeloid Leukemia Drug Sales Volume (K Pcs) Forecast by Type (2018-2025)
Figure United States Relapsed Acute Myeloid Leukemia Drug Sales Volume (K Pcs) Forecast by Type (2018-2025)
Figure United States Relapsed Acute Myeloid Leukemia Drug Sales Volume (K Pcs) Forecast by Type in 2025
Table United States Relapsed Acute Myeloid Leukemia Drug Sales Volume (K Pcs) Forecast by Application (2018-2025)
Figure United States Relapsed Acute Myeloid Leukemia Drug Sales Volume (K Pcs) Forecast by Application (2018-2025)
Figure United States Relapsed Acute Myeloid Leukemia Drug Sales Volume (K Pcs) Forecast by Application in 2025
Table United States Relapsed Acute Myeloid Leukemia Drug Sales Volume (K Pcs) Forecast by Region (2018-2025)
Table United States Relapsed Acute Myeloid Leukemia Drug Sales Volume Share Forecast by Region (2018-2025)
Figure United States Relapsed Acute Myeloid Leukemia Drug Sales Volume Share Forecast by Region (2018-2025)
Figure United States Relapsed Acute Myeloid Leukemia Drug Sales Volume Share Forecast by Region in 2025
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources

More Publications

Need Help?

Ask a Question

Market Reports

All Categories